ALBANY, New York, December 7, 2017 /PRNewswire/ --
Transparency Market Research states that the key players
operating in the global erythropoietin drugs market are focusing on
product development. The intensifying competition is expected to
coax players to look for newer distributorship in the coming years.
The research report, identifies Merck & Co., Inc., Amgen Inc.,
F. Hoffmann-La Roche Ltd., Novartis AG, and GlaxoSmithKline plc as
the important players in the global market. In the coming years,
these players also likely to emphasize on strategic acquisitions
with primary focus on production of erythropoietin drugs to earn
better returns on investments. Companies will also look like at
making the most of the incentives offered by the government for
research on chronic diseases.
According to the research report, the global erythropoietin
drugs market is expected to be worth US$19,379.2 mn by the end of 2025 as it surges at
CAGR of 7.5% from 2017 to 2025. Out of the various applications of
erythropoietin drugs, cancer is expected to be the highest revenue
contributor. The high diagnosis rate of cancer and a strong
pipeline erythropoietin drugs for cancer have expected to fuel the
growth of this segment. Geographically, North America is slated to remain the key
regional market due to better research and development grants
offered by the governments.
View Report at
https://www.transparencymarketresearch.com/erythropoietin-market.html
Demand for Precise Clinical Testing to Boost Usage of
Erythropoietin Drugs
The global erythropoietin drugs market has been garnering a good
momentum in the past few years as the diagnostic rate of chronic
conditions has been on a consistent rise. For instance, in European
Union cancer has been growing significantly, and according to
research article European cancer mortality predictions for the year
2017, published in US National Library of Medicine, around 13,
73,500 cancer deaths predicted in 2017. Further, strong pipeline of
erythropoietin drugs, of which cancers account for a major share,
is expected to aid to the market growth of the segment in the near
future. Meanwhile, the rising rate of renal diseases such as
chronic kidney disease is expected to contribute to the overall
revenue. The prominent genetic mutation rates which is the primary
cause of renal disease are anticipated to propel the market growth
of the segment.
Request to View Sample Copy of Report -
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1856
Additionally, it is difficult to manufacture biosimilars or
generic versions of biologic erythropoietin drugs as compared to
biosimilar drugs. Furthermore, unique design of erythropoietin
drugs which enables precise clinical testing and offers better
outcomes in clinical trials. Additionally, fewer side effects of
these drugs makes them a preferred choice of treatment. The demand
for erythropoietin drugs for treating anemia is also expected to be
a profiting trend for the vendors in the global market.
Request Erythropoietin Drugs Market Report
Brochure @
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1856
High Pricing to Dissuade Consumption
However, lack of capping on pricing of erythropoietin drugs by
hospital laboratories in certain countries of Europe is likely to hamper the market in the
region during the forecast period. Furthermore, poor healthcare
facilities in developing parts of the world are also expected to
restrain the market growth in the foreseeable future. Additionally,
the lack of diagnoses of chronic diseases in the rural parts of
emerging economies are also anticipated to have a negative impact
on the global erythropoietin drugs market.
Global Erythropoietin Drugs Market Report is
available @ US$ 5795
About TMR
Transparency Market Research (TMR) is a global market
intelligence company providing business information reports and
services. The company's exclusive blend of quantitative forecasting
and trend analysis provides forward-looking insight for thousands
of decision makers. TMR's experienced team of analysts,
researchers, and consultants use proprietary data sources and
various tools and techniques to gather and analyze information.
Contact
Transparency Market Research
State Tower
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free:
866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com
TMR Blog: http://www.theglobalhealthnews.com/